Oral Ibuprofen for the Treatment of PDA in Preterm Neonates: Urgent Need for a Safer Alternative to Hyperosmolar Formulations
Paediatr Drugs
.
2024 Mar;26(2):205-207.
doi: 10.1007/s40272-023-00617-3.
Epub 2024 Jan 27.
Authors
Jaemaela Del Rosario
1
,
Gerhard Fusch
2
,
Ali McBryde
1
,
Katelyn Sushko
3
,
John van den Anker
4
5
,
Samira Samiee-Zafarghandy
6
Affiliations
1
Neonatal Intensive Care Unit, McMaster Children's Hospital, Hamilton, ON, Canada.
2
Department of Pediatrics, Division of Neonatology, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4 L8, Canada.
3
Faculty of Health Sciences, School of Nursing, McMaster University, Hamilton, ON, Canada.
4
Department of Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland.
5
Division of Clinical Pharmacology, Children's National Health System, Washington, DC, USA.
6
Department of Pediatrics, Division of Neonatology, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4 L8, Canada. samiees@mcmaster.ca.
PMID:
38280107
DOI:
10.1007/s40272-023-00617-3
No abstract available
Publication types
Letter
MeSH terms
Administration, Oral
Ductus Arteriosus, Patent* / drug therapy
Humans
Ibuprofen* / adverse effects
Infant, Low Birth Weight
Infant, Newborn
Infant, Premature
Substances
Ibuprofen